Alder Biopharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Alder Biopharmaceuticals's estimated annual revenue is currently $5.4M per year.
- Alder Biopharmaceuticals received $287.5M in venture funding in February 2018.
- Alder Biopharmaceuticals's estimated revenue per employee is $77,500
- Alder Biopharmaceuticals's total funding is $525M.
Employee Data
- Alder Biopharmaceuticals has 70 Employees.
- Alder Biopharmaceuticals grew their employee count by -34% last year.
Alder Biopharmaceuticals's People
| Name | Title | Email/Phone |
|---|
Alder Biopharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $5.7M | 37 | 42% | N/A | N/A |
#5 | $1.4M | 18 | -10% | N/A | N/A |
#6 | $3.7M | 48 | -21% | $16M | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $0.8M | 5 | -81% | N/A | N/A |
#9 | $2.5M | 16 | -27% | N/A | N/A |
#10 | $0.8M | 5 | -17% | N/A | N/A |
What Is Alder Biopharmaceuticals?
Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles: As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases. As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
$525M
Total Funding
70
Number of Employees
$5.4M
Revenue (est)
-34%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Alder Biopharmaceuticals News
... market players in Th17 Driven disease Treatment market are AbbVie, Alexion Pharmaceuticals, Alder Biopharmaceuticals, Astellas Pharma.
... Grevas, made $286,960 in illegal profits from the purchase and sale of securities in Washington state-based Alder BioPharmaceuticals,...
A billionaire investor of Athira Pharma is calling for the ouster of ... the former chief business officer at Alder Biopharmaceuticals and...
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY), a Valby, Denmark-based global pharmaceutical company specialized in brain diseases, is to acquire Alder BioPharmaceuticals (NASDAQ: ALDR), a Bothell, Washington, USA-based company committed to advancing migraine treatment and prevention, in a transaction ...
Alder’s lead drug candidate is eptinezumab, a monoclonal antibody for migraine prevention that targets the calcinonin gene-related peptide, or CGRP, and has been submitted to the FDA for approval, with the agency expected to rule on the drug by Feb. 21, 2020. Shares of Alder were up 83 percent ...
Other Companies in Bothell
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $18.3M | 70 | 6% | N/A |
#2 | $9.3M | 71 | 58% | N/A |
#3 | $19.1M | 73 | 6% | N/A |
#4 | $9.5M | 73 | N/A | N/A |
#5 | $9.5M | 73 | -6% | N/A |
Alder Biopharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2005-08-16 | $11.1M | A | Multiple | Article |
| 2006-07-10 | $16.0M | B | H.I.G. Ventures | Article |
| 2008-01-14 | $40.0M | C | TPG Biotech, Delphi Ventures | Article |
| 2012-04-20 | $38.0M | D | Novo Ventures | Article |
| 2012-08-28 | $3.5M | Undisclosed | Bristol-Myers Squibb | Article |
| 2015-01-09 | $177.0M | Undisclosed | Credit Suisse | Article |
| 2015-06-26 | $230.0M | Undisclosed | Credit Suisse | Article |
| 2017-07-14 | $172.5M | Undisclosed | Leerink Partners LLC | Article |
| 2018-01-09 | $100.0M | Undisclosed | Redmile Group LLC | Article |
| 2018-01-30 | $230.0M | Undisclosed | Goldman Sachs & Co. LLC, | Article |
| 2018-02-05 | $287.5M | Undisclosed | Goldman Sachs & Co. LLC, | Article |